A French multicenter study of primary Sjogren's syndrome (pSS) patients fulfilling the American–European Consensus Group criteria or enlarged American–European Consensus Group criteria were retrospectively studied based on having biopsy-proven renal involvement.
All News
Aromatase inhibitors (AI) are often given in the setting of estrogen receptor-positive (ER+) breast cancer therapy.
Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.
MedScape has reported that the US Food and Drug Administration (FDA) has approved lifitegrast ophthalmic solution (Xiidra, Shire) for the treatment of signs and symptoms of dry eye disease.
Dr. Cush reviews highlights published this week at RheumNow.com.
In April and May 2016, RheumNow sent 82 tweets regarding news, research and teaching points that strongly impacted the rheumatology community and resulted in a reach of 203,500 impressions, with 136 mentions, and over 6378 visits to RheumNow.com. Here are the top tweets from April and May.
Dr. Jack Cush reviews the rheumatology highlights from the news, media, and journals from this past week:
Karmacharya and colleages have reviewed 33 cases of rituximab-induced serum sickness. Half of these patients had the classic triad of SS fever, rash, and arthralgia and a self-limiting course. The time to onset after infusion was greater with the first dose of rituximab c
The population prevalence of Sjogrens syndrome is 0.2%, with an incidence of 4 cases per 100,000 per year. Sjogrens is 20 times more common in females than males.
A population based study from Taiwan shows that Sjogren's syndrome, to have a prevalence of 0.05%. The prevalence of the syndrome, however, was 10 times higher among women (0.10%) compared to men (0.01%). Overall, having an affected first-degree relative with Sjogren's syndrome carried
